new strategy for malignant transformation of mature cystic teratoma

new strategy for malignant transformation of mature cystic teratoma - new strategy for malignant transformation of mature cystic teratoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013828

Enrollment

Registered

2014-05-20

Start date

2014-05-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian mature cystic teratoma with malignant transformation

Interventions

concurrent chemoradiation for Ovarian cancer with Stage I, or II intra-venous chemotherapy using Paclitaxel, Cisplatin, and 5-FU for Ovarian cancer with stage III or IV

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: ovary is surgically removed,and diagnosed of malignant transformation of ovarian mature cystic teratoma squamous cell carcinoma be able to get informed concent by document

Exclusion criteria

Exclusion criteria: past or present history of therapy for other malignancy

Design outcomes

Primary

Measure	Time frame
OS	—

Countries

Japan

Contacts

Public ContactMamiko Onuki

University of Tsukuba DIvision of medicine

monuki@md.tsukuba.ac.jp029-853-3073

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026